COEXISTING HYPERPARATHYROIDISM WITH THYROTOXICOSIS

被引:19
作者
MCGOWAN, DM
VASWANI, A
SHPERLING, I
机构
[1] WINTHROP UNIV HOSP,DIV ENDOCRINOL,259 1ST ST,222 STN PLAZA N,MINEOLA,NY 11501
[2] SUNY STONY BROOK,STONY BROOK,NY 11794
关键词
HYPERCALCEMIA; HYPERPARATHYROIDISM; THYROTOXICOSIS; HYPERTHYROIDISM; PARATHYROID HORMONE; CALCIUM;
D O I
10.1007/BF03346819
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The coexistence of hyperparathyroidism complicating thyrotoxicosis is quite rare. We report the case of one patient who presented with thyrotoxicosis, (total thyroxine of 15.1-mu-g/dl (5-13), free thyroxine index of 18 (4-15) and triiodothyronine by RIA of 305 ng/dl (70-230) and asymptomatic hypercalcemia of 15 mg/dl (8.5-10.6), who was also initially noted to have an elevated (C-terminal) serum immunoreactive parathyroid hormone (iPTH) level of 8,800 pg/ml (50-340). With propylthiouracil and propranolol, however, this patient became normocalcemic with a decrease in iPTH values to 714 pg/ml. As the patient was tapered from medication, after being rendered euthyroid, a recurrence of hypercalcemia with rising iPTH levels occurred. PTH levels should be helpful in defining coexisting hyperparathyroidism in patients with thyrotoxicosis since in the latter iPTH is usually suppressed. Our findings support the recommendation that in patients suspected of having both hyperparathyroidism and hyperthyroidism, a diagnosis of the former can only be made with certainty after the patient has been rendered euthyroid with persistently elevated serum calcium and iPTH levels. While there are no clinical features which permit the easy identification of patients who present with dual lesions, the determination of iPTH values may be the most consistently helpful test initially, whereas other parameters such as vitamin D, serum phosphate are less reliable.
引用
收藏
页码:305 / 310
页数:6
相关论文
共 33 条
[21]   RADIOIMMUNOASSAY FOR THE MIDDLE REGION OF HUMAN PARATHYROID-HORMONE USING AN HOMOLOGOUS ANTISERUM WITH A CARBOXY-TERMINAL FRAGMENT OF BOVINE PARATHYROID-HORMONE AS RADIOLIGAND [J].
MALLETTE, LE ;
TUMA, SN ;
BERGER, RE ;
KIRKLAND, JL .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1982, 54 (05) :1017-1024
[22]  
MANDERLIER T, 1974, ANN ENDOCRINOL-PARIS, V35, P185
[23]  
MAXON HR, 1978, SURG GYNECOL OBSTET, V147, P694
[24]   NEUROENDOCRINE MODULATION OF CALCITONIN AND PARATHYROID-HORMONE IN MAN [J].
METZ, SA ;
DEFTOS, LJ ;
BAYLINK, DJ ;
ROBERTSON, RP .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1978, 47 (01) :151-159
[25]  
MOSKELIDE L, 1977, ACTA ENDOCRINOL-COP, V85, P515
[26]  
PICCIONE W, 1984, SURGERY, V9, P1009
[27]   CONCURRENT HYPERTHYOIDISM AND HYPERPARATHYROIDISM [J].
RAO, KM .
BRITISH JOURNAL OF SURGERY, 1970, 57 (11) :868-&
[28]   TREATMENT OF THYROTOXIC HYPERCALCEMIA WITH PROPRANOLOL [J].
RUDE, RK ;
OLDHAM, SB ;
SINGER, FR ;
NICOLOFF, JT .
NEW ENGLAND JOURNAL OF MEDICINE, 1976, 294 (08) :431-433
[29]   ORAL PROPRANOLOL IN HYPER-CALCEMIA ASSOCIATED WITH APATHETIC THYROTOXICOSIS [J].
SHAHSHAHANI, MN ;
PALMIERI, GMA .
AMERICAN JOURNAL OF THE MEDICAL SCIENCES, 1978, 275 (02) :199-202
[30]   HYPERCALCEMIA IN HYPERTHYRODISM ROLE OF AGE AND GOITER TYPE [J].
SZABO, Z ;
RITZL, F .
KLINISCHE WOCHENSCHRIFT, 1981, 59 (06) :275-279